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Summary: 
Faecal microbiome transplantation (FMT) has generated huge recent interest, as it presents a 
potential solution to a significant clinical problem - the increasing incidence of Clostridium difficile 
infection.  In the short term, however, there remain many practical questions regarding its use, 
including the optimal selection of donors, material preparation and the mechanics of delivery.  In the 
longer term, enhanced understanding of the mechanisms of action of FMT may potentiate novel 
therapies, such as targeted manipulation of the microbiome in C. difficile infection and beyond.  
 
 
Introduction: 
The ĐoŶĐept of ͚ĐoloŶisatioŶ resistaŶĐe͛ - the ability of the healthy gut microbiome to inhibit 
colonisation and overgrowth by invading microorganisms – has been recognised for over forty years1.  
It is similarly well-established that perturbation of the gut microbiome, or ͚dysďiosis͛ (as may occur in 
response to antibiotics, along with other triggers) disrupts colonisation resistance, with Clostridium 
difficile infection (CDI) with associated diarrhoea being the archetypal clinical manifestation.   
 Limitations of the current antibiotic treatment for CDI have driven the search for novel treatments, 
with one option being faecal microbiome transplantation (FMT), i.e. generation of a liquidised 
bacterial suspension from the faeces of healthy donors, and delivery of this into the gastrointestinal 
(GI) tract of affected patients.  Assessment of FMT in the setting of CDI has demonstrated that this is a 
viable treatment option.   
 
The recognition that dysregulation of the gut microbiome is characteristic not just of CDI but a wide 
variety of human diseases2 raises the possibility that manipulation of the composition or function of 
the gut microbiome could develop beyond CDI to be used more broadly as a therapeutic strategy.   
   
 
Clostridium difficile infection: a global problem: 
Clostridium difficile infection ranges in clinical severity from mild diarrhoea to the life-threatening 
states of pseudomembranous colitis and toxic megacolon.  Whilst the increasing impact of CDI over 
the past 15 years has been felt globally (with antibiotic use being the predominant risk factor), the 
burden has been greatest in Europe and North America3.  One major factor contributing to this has 
been the arrival of newer, more virulent and increasingly antibiotic-resistant strains, such as NAP1/ 
ribotype 027.  Whilst CDI acquisition still occurs most commonly in healthcare facilities, there has 
been increasing recognition of community-associated CDI, even amongst conventionally low risk 
groups such as children4. 
 
Standard therapy for CDI involves metronidazole for mild disease, and vancomycin for severe or 
recurrent CDI (with pulsed/ tapered regimens typically being used in recurrent disease5).  Worryingly, 
however, the response to metronidazole has declined from approximately 90% to 70% over the past 
decade6.  A further serious concern has been the increasing recognition of recurrent CDI.  Recurrence 
occurs in approximately 20% of patients treated initially with either metronidazole or vancomycin 7; 
the risk of further recurrence increases to 40% after a first recurrence, rising to 60-70% after more 
than two recurrences8.  The presence of just three clinical criteria (age > 65 years, severe disease and 
continued use of antibiotics after treating the initial CDI episode) are predictive of an almost 90% 
relapse rate9.   
 
A number of different approaches have been proposed to address this problem, including intravenous 
immunoglobulin, probiotics, toxin binding and new antibiotics.  An example of the latter is 
fidaxomicin, a macrocyclic antibiotic of narrow spectrum that is now approved for the treatment of 
CDI in Europe and North America following the outcomes of two randomised controlled trials.  
However, studies to date have not investigated the efficacy of fidaxomicin in cases of recurrent CDI, 
and alternative therapeutic strategies have been proposed. 
 
 
Faecal microbiome transplantation (FMT): 
i.  Efficacy: 
The recognition of CDI as a condition representing the loss of colonisation resistance through 
antibiotic-associated gut dysbiosis prompted the hypothesis that reconstitution of the normal gut 
microbiota with FMT could be an effective therapeutic strategy.  Many different techniques for the 
provision of FMT have been described, all with similar principles: collection of stool from a healthy 
donor (who has undergone screening for transmissible infections and has not recently used 
antibiotics); homogenisation of stool (often in a domestic blender) and filtration of large particulate 
matter; and administration of the slurry into either the upper GI tract (via nasogastric or 
nasoduodenal tube), or the lower GI tract (via enema or colonoscopy).   
 
At present, FMT to treat CDI has been described for over 500 patients in the literature, with efficacy 
rates of over 90%.  The time from receiving FMT until response is variable; a median time to 
resolution of one day was reported in a cohort receiving colonoscopic FMT10.  Although uncontrolled 
case series of FMT for CDI have been reported for over a decade, the first randomised controlled trial 
comparing FMT to standard therapy was published only recently11.  Patients with recurrent CDI were 
randomised to one of three treatment arms: vancomycin 500mg four times daily for four or five days 
followed by bowel lavage and then FMT; standard vancomycin therapy (500mg four times daily for 14 
days); or standard vancomycin therapy with bowel lavage.  The primary outcome was resolution of 
diarrhoea without relapse at 10 weeks.  FMT consisted of at least 50g of fresh stool from donors 
unrelated to the recipient that was blended with 500 millilitres of normal saline and filtered before 
immediate administration via a nasoduodenal tube.  Trial participants who failed to respond in their 
initial treatment arm were offered FMT ͞off protocol͟.  The trial was stopped early (after randomising 
42 patients) following an interim analysis which demonstrated significantly improved outcomes from 
FMT compared to other treatment arms, with cure rates of 89% in the FMT group (94% after two 
infusions), 31% in the standard vancomycin group, and 23% in the vancomycin-bowel lavage group.   
 
ii.  Safety and acceptability: 
One major concern regarding FMT has been the potential for transmission of infectious diseases from 
donor to recipient, although no such cases have been reported.  As such, donor risk assessment 
through clinical, social and travel assessment – along with blood and stool screening for transmissible 
diseases - has been recommended12 and widely-instigated (Table 1). 
 
FMT appears to be well-tolerated with few significant side effects.  In the trial of van Nood et al, the 
most common side effects included diarrhoea, cramping and belching, consistent with other studies11.  
Symptoms tended to resolve quickly without specific intervention.  Aspiration was not observed when 
500 millilitres of solution was infused over approximately 20 minutes into these patients11.  No 
significant adverse sequelae have been reported in FMT recipients over longer term follow up10.   
 
Poor acceptability of FMT to patients has been a concern, but this is not borne out in practice.  Many 
patients with recurrent CDI (and other conditions for which FMT has been proposed as therapy13) 
actively seek out FMT providers, often via online forums.  Furthermore, those who received FMT 
generally found the procedure acceptable; 97% of patients who had undergone FMT for recurrent CDI 
reported willingness to undergo further FMT if required, with 53% stating that they would choose 
FMT as first-line treatment before antibiotics10.   
 
 
iii.  Practical aspects of FMT administration: 
Recruitment and screening of stool donors can be a difficult and expensive process.  Therefore, the 
ability to use pre-sĐreeŶed ͚uŶiversal doŶors͛ - who have provided stool that can be processed into 
FMT in advance, then frozen prior to thawing on the day of use - is attractive.  A standardised 
protocol for frozen FMT preparation (using glycerol as a cryopreservative) has been recently 
reported14, with efficacy against recurrent CDI described of at least 90% from colonoscopic FMT using 
both fresh and frozen stool.   
 
The mechanics of preparing the solution have varied between centres.  Typically 50 – 60g of stool is 
homogenised with 250 – 300ml of diluent.  Saline, water and even milk have all been used 
successfully as diluents.  Most centres administer large-volume bowel lavage prior to FMT, often 
regardless of the route of administration (to remove residual clostridial organisms and any antibiotic 
remnants).  Recipients typically stop antibiotics anywhere between one and three days prior to the 
transplant, although this has not been compared in a trial setting to continuing antibiotics up to or 
even after the procedure.  It has become conventional practice to administer loperamide prior to 
colonoscopic administration (to aid retention), and a proton pump inhibitor prior to upper GI 
administration (to minimise gastric acidity).  Whether upper or lower GI administration of FMT is 
more efficacious has been recently addressed in an open-label randomised controlled trial15; there 
was no significant difference in outcome between administration colonoscopically or via a nasogastric 
tube.    
 
 
iv.  A viable treatment option: 
Consensus guidelines with regards to the role of FMT in CDI treatment have recently been published 
and broadly adopted12 (Table 2).  Some authorities argue that FMT should be considered early in the 
clinical course of CDI, and even as first-line therapy16.  Experience of the use of FMT in severe CDI is 
more limited, but it appears effective in this setting17.  Recent data suggest that FMT is of similar 
efficacy in immunocompromised patients, with no additional risk of infectious complications6.   
 
FMT has been shown to be more cost-effective than other treatment modalities for recurrent CDI18.  
Based on the available evidence, FMT is now recommended as treatment for recurrent CDI in 
professional guidelines both from the USA5 and the UK, where FMT for recurrent CDI was recently 
advocated for use by NICE19.   
 
 
Gut microbiome in human disease: from FMT to novel therapies: 
Recent research using molecular techniques (including sequencing of 16S rRNA genes and metabolic 
profiling platforms) has identified distinctive alterations in the composition and function of the gut 
microbiome accompanying a wide range of human diseases2, 20.  Whilst many of these are primary GI/ 
liver conditions (including inflammatory bowel disease, colorectal cancer and non-alcoholic fatty liver 
disease), many are not, including obesity, diabetes, and even neurological conditions.  Whether such 
dysregulation of the gut microbiome in disease states is causal or consequential remains largely 
unclear, although there is certainly now some evidence for the former: for instance, obese and lean 
phenotypes can be induced in germ-free mice by transfer of faecal microbiota from human twins 
discordant for obesity21.  Similarly, men with metabolic syndrome who received FMT from lean male 
donors demonstrated an increase in gut microbial diversity and improvement in peripheral insulin 
sensitivity, when neither of these changes were seen when these individuals received FMT of their 
own processed stool22. 
 
Such findings have clear implications for the screening of FMT donors; potential donors with any of 
the conditions in which gut microbiome dysregulation have been consistently linked are typically 
excluded. Additionally, given that FMT has demonstrated that sustainable alterations in the gut 
ŵiĐroďioŵe are aĐhievaďle, the ŵaŶipulatioŶ of the gut ŵiĐroďioŵe͛s struĐture (or ŵodifiĐatioŶ of its 
functional activity) has been highlighted as a potential new mechanism of therapeutic intervention for 
a broader range of diseases23.  
 
If ͚ŵiĐroďioŵe therapeutiĐs͛ are truly to represent a novel treatment modality, then the means by 
which such therapy may be optimally administered must be established.  FMT has already been used 
as an experimental treatment for a number of conditions other than CDI, although the results to date 
have been highly variable24.  Furthermore, FMT in itself clearly has significant drawbacks (not least its 
unpalatable nature), and other techniques of achieving manipulation of the microbiome merit 
exploration.  One favoured idea is the administration of a ͚defined microbiome ecosystem͛ of 
selectively-cultured bacterial strains (ideally either as a drink or an oral capsule containing a mixture 
of lyophilised bacteria) that target specific dysregulated components of the gut microbiome25.  An 
alternative strategy may be to design drugs that modulate microbial signalling or enzymatic activities 
and alter host metabolism23.   
 
 
Conclusion: 
FMT is gaining widespread acceptance as a viable treatment option for CDI.  Ongoing trials will help to 
clarify the uncertainties that still exist regarding the optimal means of administration.  The recent 
identification of gut microbiome dysregulation as a feature of a broad range of diseases has raised the 
possibility that the success of FMT for CDI may be transferrable to other conditions, although the 
potential contribution of the microbiome to the pathogenesis of many of these diseases is much less 
well characterised than in CDI.  Mechanisms of manipulating the gut microbiome in a more targeted 
way than FMT are clearly of great potential interest.  The key next step is to understand the 
mechanism by which FMT exerts its efficacy in CDI, and further to explore the interaction between 
the gut microbiome and host metabolism in both health and disease states (and the factors that 
influence this, including diet and antibiotic use).  The true potential of ͚ŵiĐroďioŵe therapeutiĐs͛ may 
then begin to be realised.   
 
Conflicts of interest:  None. 
 
Funding:  This work was supported by the National Institute of Health Research (NIHR) Biomedical 
Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London, and by 
the Imperial College Healthcare Charity [grant number 141516]. 
 
Figures: 
Table 1:  Screening protocol for transmissible diseases for potential donors to an FMT programme.  
This is the screening protocol currently used in the programme at Imperial College London; assays are 
repeated six monthly.  In addition, donors complete detailed questionnaires regarding their medical, 
family, and medication history when being considered as donors, and questionnaires regarding recent 
symptoms suggestive of GI disease or infection (as well as recent travel) when donating stool for 
processing into FMT.  
 
Table 2:  Conventional indications and contraindications for use of FMT in the treatment of 
Clostridium difficile infection:  (Adapted from 12).  As described in the text, arguments have been 
made for using FMT earlier in the clinical course of CDI16, and that the concerns regarding the risk of 
FMT to treat CDI in immunosuppressed states may be overestimated6. 
 
References: 
1. Lawley TD, Walker AW.  Intestinal colonization resistance.  Immunology 2013; 138(1): 1 – 11. 
 
2.  Holmes E, Li JV, Athanasiou T, Ashrafian H, Nicholson JK.  Understanding the role of gut 
microbiome-host metabolic signal disruption in health and disease.  Trends Microbiol 2011; 19(7): 349 
– 359. 
 
3.  Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH.  The 
changing epidemiology of Clostridium difficile infections.  Clin Microbiol Rev 2010; 23(3): 529 - 549. 
 
4.  Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister 
AR.  The epidemiology of community-acquired Clostridium difficile infection: a population-based 
study.  Am J Gastroenterol 2012; 107(1): 89 – 95.  
 
5.  Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, 
Mellow M, Zuckerbraun BS.  Guidelines for diagnosis, treatment, and prevention of Clostridium 
difficile infections.  Am J Gastroenterol 2013; 108(4): 478 – 498. 
 
6.  Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, Aroniadis O, Barto A, Borody T, 
Giovanelli A, Gordon S, Gluck M, Hohmann EL, Kao D, Kao JY, McQuillen DP, Mellow M, Rank KM, Rao 
K, Ray A, Schwartz MA, Singh N, Stollman N, Suskind DL, Vindigni SM, Youngster I, Brandt L.  Fecal 
microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients.  
Am J Gastroenterol 2014; 109(7): 1065 – 1071. 
 
7.  Pépin J, Routhier S, Gagnon S, Brazeau I.  Management and outcomes of a first recurrence of 
Clostridium difficile-associated disease in Quebec, Canada.  Clin Infect Dis 2006; 42(6): 758 – 764.  
 
8.  McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN.  Recurrent Clostridium 
difficile disease: epidemiology and clinical characteristics.  Infect Control Hosp Epidemiol 1999; 20(1): 
43 – 50. 
 
9.  Hu MY, Katchar K, Kyne L, Maroo S, Tummala S, Dreisbach V, Xu H, Leffler DA, Kelly CP.  Prospective 
derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.  
Gastroenterology 2009; 136(4): 1206 – 1214. 
 
10.  Brandt LJ, Aroniadias OC, Mellow M, Kanatzar A, Kelly C, Park T, Stollman N, Rohlke F, Surawicz C.  
Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile 
infection.  Am J Gastroenterol 2012; 107(7): 1079 – 1087. 
 
11.  van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, 
Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ.  Duodenal infusion of donor feces for 
recurrent Clostridium difficile.  N Engl J Med 2013; 368(5): 407 – 415. 
 
12.  Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly C, Khoruts A, Louie T, 
Martinelli LP, Moore TA, Russell G, Surawicz C; Fecal Microbiota Transplantation Workgroup.  Treating 
Clostridium difficile infection with fecal microbiota transplantation.  Clin Gastroenterol Hepatol 2011; 
9(12): 1044 – 1049. 
 
13.  Swaminath A.  The power of poop: patients getting ahead of their doctors using self-administered 
fecal transplants.  Am J Gastroenterol 2014; 109(5): 777 – 778. 
 
14.  Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A.  Standardized frozen preparation for 
transplantation of fecal microbiota for recurrent Clostridium difficile infection.  Am J Gastroenterol 
2012; 107(5): 761 – 767. 
 
15.  Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, Alm EJ, Gevers D, Russell GH, 
Hohmann EL.  Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen 
inoculum from unrelated donors: a randomized, open-label, controlled pilot study.  Clin Infect Dis 
2014; 58(11): 1515 – 1522. 
 
16.  BraŶdt LJ, Borody TJ, Caŵpďell J.  EŶdosĐopiĐ feĐal ŵiĐroďiota traŶsplaŶtatioŶ: ͞first-liŶe͟ 
treatment for severe Clostridium difficile infection?  J Clin Gastroenterol 2011; 45(8): 655 – 657. 
 
17.  Weingarden AR, Hamilton MJ, Sadowsky MJ, Khoruts A.  Resolution of severe Clostridium difficile 
infection following sequential fecal microbiota transplantation.  J Clin Gastroenterol 2013; 47(8): 735 – 
737. 
 
18.  Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN.  Cost-effectiveness of competing 
strategies for management of recurrent Clostridium difficile infection: a decision analysis.  Clin Infect 
Dis 2014; 58(11): 1507 – 1514. 
 
19.  NICE.  Faecal microbiota transplant for recurrent clostridium difficile infection, interventional 
procedure guidance IPG 485, 2014, http://guidance.nice.org.uk/IPG485 . 
 
20.  Nicholson JK, Holmes E, Kinross J, Burcellin R, Gibson G, Jia W, Pettersson S.  Host-gut microbiota 
metabolic interactions.  Science 2012; 336(6086): 1262 – 1267. 
 
21.  Ridura VK, Fiath JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain 
JR, Muehlbauer MJ, Ilkayeva O, Semenkovich CF, Funai K, Hayashi DK, Lyle BJ, Martini MC, Ursell LK, 
Clemente JC, Van Treuren W, Walters WA, Knight R, Newgard CB, Heath AC, Gordon JI.  Gut 
microbiota from twins discordant for obesity modulate metabolim in mice.  Science 2013; 341(6150): 
1241214. 
 
22.  Vrieze A, van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, Dallinga-Thie GM, 
Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JET, Bloks VW, Groen 
AK, Heilig HGHJ, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JBL, Nieuwdorp M.  Insulin sensitivity 
in individuals with metabolic syndrome.  Gastroenterology 2012; 143(4): 913 – 916. 
 
23.  Holmes E, Li JV, Marchesi JR, Nicholson JK.  Gut microbiota composition and activity in relation to 
host metabolic phenotype and disease risk.  Cell Metab 2012; 16(5): 559 – 564. 
 
24.  Borody TJ, Brandt LJ, Paramsothy S.  Therapeutic faecal microbiota transplantation: current status 
and future developments.  Curr Opin Gastroenterol 2014; 30(1): 97 – 105.  
 
25.  Petrof EO, Khoruts A.  From stool transplants to next-generation microbiota therapeutics.  
Gastroenterology 2014; 146(6): 1573 – 1582. 
 
 
 
 
